Romeo Romagnoli

This inventor holds 11 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: King Pharmaceuticals Research and Development, Inc., Pharmacia & Upjohn, The University of Ferrara. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Romeo Romagnoli. Retrieved from https://idiyas.com/inventor/romeo-romagnoli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 2)

% Patents Active = 54.5

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Milan, IT (2003)
Ferrara, IT (2000 - 2016)

Company Filing History:

4 out of 23

King Pharmaceuticals Research and Development, Inc.

The University of Ferrara

patents

4. 1 out of 2

Associazione Per La Lotta Alla Talassemia Di Ferrara

patents

5. 1 out of 5

Associazione Veneta Per La Lotta Alla Talassemia

patents

6. 1 out of 1

Istituto Di Ricerca Pediatrica Citta Della Speranza

patent

7. 1 out of 631

Katholieke Universiteit Leuven

patents

8. 1 out of 26

Pharmacia Italia S.p.a.

patents

9. 1 out of 43

Universitá Degli Studi Di Padova

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319678 - Thioridazine derivatives and their use for the treatment of cancer (2025-06-03),

2. 9278958 - Anti-cancer compounds (2016-03-08),

3. 7897596 - [object Object] (2011-03-01),

4. 7855209 - [object Object] (2010-12-21),

5. 7449490 - Pharmaceutically active compounds and methods of use (2008-11-11),

6. 7396851 - Heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin A for the treatment of β-thalassaemia (2008-07-08),

7. 7101905 - Pharmaceutically active compounds and methods of use (2006-09-05),

8. 6753316 - Acryloyl derivatives analogous to distamycin, process for preparing them, and their use as antitumor agents (2004-06-22),

9. 6596845 - Cinnamoyl distamycin analogous derivatives, process for their preparation, and their use as antitumor agents (2003-07-22),

10. 6458768 - Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor agents (2002-10-01),

11. 6153642 - Benzoheterocyclic distamycin derivatives, process for preparing them, (2000-11-28),

Title: The Innovative Contributions of Romeo Romagnoli

Introduction

Romeo Romagnoli is a distinguished inventor based in Ferrara, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-cancer compounds. With a total of 11 patents to his name, Romagnoli's work has the potential to impact cancer treatment significantly.

Latest Patents

Among his latest patents are innovative compounds related to thioridazine derivatives. These compounds are particularly suitable for the treatment of pediatric acute myeloid leukemia, specifically targeting the KMT2A/AFDN rearrangement. Additionally, he has developed anti-cancer compounds that exhibit cytostatic activity against tumor cells, showcasing his commitment to advancing cancer therapies.

Career Highlights

Throughout his career, Romagnoli has worked with notable companies such as King Pharmaceuticals Research and Development, Inc. and Pharmacia & Upjohn S.p.a. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Romagnoli has collaborated with esteemed colleagues, including Pier Giovanni Baraldi and Paolo Cozzi. These partnerships have fostered a collaborative environment that enhances the innovation process in their research endeavors.

Conclusion

Romeo Romagnoli's contributions to the field of pharmaceuticals, particularly in cancer treatment, highlight his role as a leading inventor. His innovative patents and collaborations reflect his dedication to improving healthcare outcomes.

Profile summary based on public USPTO records.